<p>RCB, residual cancer burden; RDBN, residual disease in breast and node; TRR, tumor response ratio.</p
Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment ...
Background: Neoadjuvant chemotherapy administered pre-operatively is the standard of care therapy fo...
Neoadjuvant chemotherapy (NAC) for breast cancer (BC) is the gold standard treatment for locally adv...
<p>RCB, residual cancer burden; RDBN, residual disease in breast and node; TRR, tumor response ratio...
Several methods are used to assess the pathologic response of breast cancer after neoadjuvant chemot...
PurposeSeveral pathologic staging systems characterize residual tumor in patients undergoing neoadju...
Complete clinical response (determined by palpation, instrumental methods, and macroscopic examinati...
Neoadjuvant chemotherapy is planned for patients with locally advanced carcinomas or with tumors pri...
Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cance...
Neoadjuvant chemotherapy (NACT) is offered to an increasing number of breast cancer (BC) patients, a...
of different definitions of pathologic complete response in operable breast cancer: a pooled analysi...
IMPORTANCE: Residual cancer burden (RCB) distributions may improve the interpretation of efficacy in...
Background: Response to neoadjuvant chemotherapy is used as an intermediate endpoint for breast canc...
Pathologic evaluation of early breast cancer after neoadjuvant therapy is essential to provide progn...
Aim. Paclitaxel based neoadjuvant chemotherapy regimen (NAT) in the setting of locally advanced brea...
Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment ...
Background: Neoadjuvant chemotherapy administered pre-operatively is the standard of care therapy fo...
Neoadjuvant chemotherapy (NAC) for breast cancer (BC) is the gold standard treatment for locally adv...
<p>RCB, residual cancer burden; RDBN, residual disease in breast and node; TRR, tumor response ratio...
Several methods are used to assess the pathologic response of breast cancer after neoadjuvant chemot...
PurposeSeveral pathologic staging systems characterize residual tumor in patients undergoing neoadju...
Complete clinical response (determined by palpation, instrumental methods, and macroscopic examinati...
Neoadjuvant chemotherapy is planned for patients with locally advanced carcinomas or with tumors pri...
Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cance...
Neoadjuvant chemotherapy (NACT) is offered to an increasing number of breast cancer (BC) patients, a...
of different definitions of pathologic complete response in operable breast cancer: a pooled analysi...
IMPORTANCE: Residual cancer burden (RCB) distributions may improve the interpretation of efficacy in...
Background: Response to neoadjuvant chemotherapy is used as an intermediate endpoint for breast canc...
Pathologic evaluation of early breast cancer after neoadjuvant therapy is essential to provide progn...
Aim. Paclitaxel based neoadjuvant chemotherapy regimen (NAT) in the setting of locally advanced brea...
Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment ...
Background: Neoadjuvant chemotherapy administered pre-operatively is the standard of care therapy fo...
Neoadjuvant chemotherapy (NAC) for breast cancer (BC) is the gold standard treatment for locally adv...